Phase 3 Readout~month

Phase 3 Topline: An Open-label Phase II/III Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembr

Drug
bnt113
Indication
Unresectable Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Cancer; Recurrent Head and Neck Cancer

Other upcoming events for BNTX

Phase 3 ReadoutPhase 3 Topline: A MASTER PHASE 1/2/3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF VARIANT
Phase 3 ReadoutPhase 3 Topline: A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BNT162b2 (LP.8.1
Phase 3 ReadoutPhase 3 Topline: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL STUDY EVALUATING THE SAFETY, TOLERA
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemot
Phase 3 ReadoutPhase 3 Topline: A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: An Open-label Phase II/III Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembr — BNTX Phase 3 Readout | BioSniper